ORLANDO, Fla., Nov. 10, 2011 /PRNewswire/ -- Theravalues, a Japan based bio-venture, announced today that Theracurmin™, its curcumin-based product, impacts positively on the prevention of heart failure and its progression for the first time in history. During the human clinical trial started with the registration in July 2010, conducted by the company with National Hospital Organization Kyoto Medical Center and University of Shizuoka, Japan, the researchers found that Theracurmin™, which is absorbed by the body at a rate 27 times higher than curcumin powder, could effectively prevent diastolic failure.
Dr. Tatsuya Morimoto, Professor at the Division of Molecular Medicine School of Pharmaceutical Sciences, at the University of Shizuoka said, "We are extremely excited to discover that Theracurmin™ has positive effects in curbing left ventricular diastolic failure at a statistically significant level." In the 24-week human trial, Theracurmin™, the absorption-enhanced curcumin invented by Theravalues, was prescribed for 30 subjects with left ventricular diastolic failure and their symptoms improved significantly. "The result of the study encourages patients and the elderly who have been suffering chronic cardiac problems," he added.
Curcumin, a polyphenol derived from turmeric (Curcuma Longa L,) has anti-inflammatory and anti-oxidant therapeutic properties. These properties effectively treat chronic inflammatory diseases. However, it has poor bioavailability due to its low oral absorption. Through Theracurmin™, Theravalues invented an innovative technology to solve this problem by creating surface controlled colloidal dispersion.
The FDA has approved Theracurmin™ for clinical trial in the United States. Last month, The University of Texas MD Anderson Cancer Center began treatment of malignant tumors caused by progressive cancer with Theracurmin™.
Mr. Hashimoto, the Representative Director and President of Theravalues said, "Theracurmin™ brings several exciting avenues of opportunity. We are confident about the potential power of Theracurmin™ not only for heart failure, but also for many incurable diseases and the maintenance of wellness of the people around the globe."
"While we were fascinated by the versatility of curcumin to help treat many diseases, its low oral absorption was the greatest challenge. Theracurmin™ improved the absorption of curcumin, making it 27 times higher than curcumin powder," said Dr. Koji Hasegawa, Director of the Division of Translational Research at National Hospital Organization Kyoto Medical Center. "In addition to its effectiveness on diastolic failure, we have been studying other application of Theracurmin™ to broaden its application into cancers, hepatic functions, skin conditions, ALS and Alzheimer's disease," he continued.
ABOUT THERAVALUES CORPORATION
Founded in 2007, Japan-based Theravalues Corporation strives to deliver better physical and mental health which gives much satisfaction to people around the world. Theravalues creates value through innovation, developing foods, medicines and technological models that achieve high satisfaction and healthy lives.
Learn more at www.theravalues.com/english
Contact: Masami Hasegawa (Theravalues, Japan)
SOURCE Theravalues Corporation